Brokers Offer Predictions for SGMO Q1 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Sangamo Therapeutics in a research report issued on Wednesday, May 14th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at $0.00 EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.34 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $6.44 million during the quarter, compared to analysts’ expectations of $7.90 million.

Other equities analysts also recently issued reports about the company. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Barclays decreased their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.50.

Sangamo Therapeutics Stock Up 4.4%

Shares of Sangamo Therapeutics stock opened at $0.47 on Friday. The stock’s 50-day simple moving average is $0.73 and its 200-day simple moving average is $1.32. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The company has a market capitalization of $107.72 million, a price-to-earnings ratio of -0.63 and a beta of 1.46.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. lifted its position in shares of Sangamo Therapeutics by 74.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 555,323 shares in the last quarter. Caption Management LLC bought a new stake in Sangamo Therapeutics during the first quarter worth approximately $37,000. OMERS ADMINISTRATION Corp increased its stake in Sangamo Therapeutics by 93.7% during the first quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 100,500 shares during the last quarter. Invesco Ltd. increased its stake in Sangamo Therapeutics by 82.8% during the first quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 219,253 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in Sangamo Therapeutics by 2,962.2% during the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after acquiring an additional 934,649 shares during the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.